A Phase 2 study investigated the efficacy of pembrolizumab, a humanised IgG4 antibody directed against surface-expressed PD-1, in patients with MSI-H/MMR-D and MSS CRC tumours, and in patients with MSI-H tumours from other sites (non-CRC). Here, PDCD1 is linked to colorectal carcinoma.